Connection
David Kao to United States Food and Drug Administration
This is a "connection" page, showing publications David Kao has written about United States Food and Drug Administration.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
1.259 |
|
|
|
-
Kao DP, Martin JL, Aquilante CL, Shalowitz EL, Leyba K, Kudron E, Reusch JEB, Regensteiner JG. Sex-differences in reporting of statin-associated diabetes mellitus to the US Food and Drug Administration. BMJ Open Diabetes Res Care. 2024 Dec 05; 12(6).
Score: 0.846
-
Kao D, Haigney MC, Mehler PS, Krantz M. Reply to Cataldo (2016): Arrhythmia associated with buprenorphine and methadone reported to the Food and Drug Administration. Addiction. 2016 09; 111(9):1686-7.
Score: 0.117
-
Kao DP, Haigney MC, Mehler PS, Krantz MJ. Arrhythmia associated with buprenorphine and methadone reported to the Food and Drug Administration. Addiction. 2015 Sep; 110(9):1468-75.
Score: 0.111
-
Kao D, Bucher Bartelson B, Khatri V, Dart R, Mehler PS, Katz D, Krantz MJ. Trends in reporting methadone-associated cardiac arrhythmia, 1997-2011: an analysis of registry data. Ann Intern Med. 2013 May 21; 158(10):735-40.
Score: 0.095
-
Kao DP, Hiatt WR, Krantz MJ. Proarrhythmic potential of dronedarone: emerging evidence from spontaneous adverse event reporting. Pharmacotherapy. 2012 Aug; 32(8):767-71.
Score: 0.089